Exchange: NASDAQ·Updated 03:59 PM EST

RGEN News

News
all
press releases
Repligen (NASDAQ:RGEN) Shares Up 6.6% - Here's Why
Repligen (NASDAQ:RGEN) Shares Up 6.6% - Here's Why...
MarketBeat
Repligen (NASDAQ:RGEN) Shares Up 6.6% - Here's Why
Repligen (NASDAQ:RGEN) Shares Up 6.6% - Here's Why...
MarketBeat
More News
Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow...
SeekingAlpha
Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eighteen research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold...
MarketBeat
William Blair Investment Management LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 57.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,415 shares of the biotechnology co...
MarketBeat
Futures Slide As AI Reckoning Claims Amazon, Intel; Oil Jumps On Hormuz Tanker Hits US futures slide with Nasdaq futures tumbling more than 2%, as the AI reckoning that started with Alphabet's record plunge claims two more megacaps: Amazon slides after a capex shock and the slowest...
Zero Hedge
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Repligen (RGEN) delivered earnings and revenue surprises of +15.22% and +1.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Stocktwits
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
Zacks
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
Zacks

Advertisement|Remove ads.